Due tonational shortageof the nebulization solutions, theformulary status of inhaler products has been temporarily adjusted to formulary, restricted to use during the albuterol/Duoneb shortage. Upon shortage resolution, these products willautomatically return to their original formulary status. SeeAlbuterol/Duoneb Shortage Mitigationfor more information. (UpdatedFeb 2023)
Brovana is a long acting beta2 agonist administered via nebulization, which leads to efficient delivery of the drug to the lungs. Some patients on the drug chronically will be admitted to the hospital and it may be desirable to continue nebulization therapy. Relative cost comparisons of Brovana versus similar agents will depend on the patient’s length of stay; because Brovana is available unit dose, for short hospital stays it will be lower cost than some 30 day inhalers -- however, it is still much higher than albuterol nebulization. It will be more expensive for a longer stay, when inhaler drugs are used for more inpatient days.
There are some SCHEDULED orders for duplicate beta-agonist therapy with Brovana nebulization and albuterol or DuoNeb nebulization. It is recommended that when this occurs, the scheduled albuterol be automatically discontinued by the pharmacist, as this is viewed duplicate therapy. In the case of DuoNeb being concurrently ordered, the ipratropium component will be continued per nebulization and the albuterol discontinued. If prescriber is a pulmonologist, contact to verify giving them together was desired before discontinuing.
Add Formweb to your mobile device
Due to national shortage of the nebulization solutions, the formulary status of inhaler products has been temporarily adjusted to formulary, restricted to use during the albuterol/Duoneb shortage. Upon shortage resolution, these products will automatically return to their original formulary status. See Albuterol/Duoneb Shortage Mitigation for more information. (Updated Feb 2023)
Brovana Medication Guide
Brovana is a long acting beta2 agonist administered via nebulization, which leads to efficient delivery of the drug to the lungs. Some patients on the drug chronically will be admitted to the hospital and it may be desirable to continue nebulization therapy. Relative cost comparisons of Brovana versus similar agents will depend on the patient’s length of stay; because Brovana is available unit dose, for short hospital stays it will be lower cost than some 30 day inhalers -- however, it is still much higher than albuterol nebulization. It will be more expensive for a longer stay, when inhaler drugs are used for more inpatient days.
There are some SCHEDULED orders for duplicate beta-agonist therapy with Brovana nebulization and albuterol or DuoNeb nebulization. It is recommended that when this occurs, the scheduled albuterol be automatically discontinued by the pharmacist, as this is viewed duplicate therapy. In the case of DuoNeb being concurrently ordered, the ipratropium component will be continued per nebulization and the albuterol discontinued. If prescriber is a pulmonologist, contact to verify giving them together was desired before discontinuing.
Reviewed: May 22, 2007, and 25 April 2017